This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
Novartis (NVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $102.10, marking a +0.13% move from the previous day.
Is Trending Stock Novartis AG (NVS) a Buy Now?
by Zacks Equity Research
Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Novartis (NVS) Fell More Than Broader Market
by Zacks Equity Research
Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
by Zacks Equity Research
Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
by Zacks Equity Research
FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
by Kinjel Shah
Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug
by Zacks Equity Research
Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis
by Zacks Equity Research
Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
4 Large Drug Stocks Trying to Survive the Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.
Company News for Feb 1, 2024
by Zacks Equity Research
Companies in The News Are: BA,MA,PSX,NVS
Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag
by Zacks Equity Research
Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.
Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
by Ahan Chakraborty
Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.
Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
by Zacks Equity Research
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.